Everest Medicines partners with Shanghai Pharma Subsidiary to accelerate the commercialization of XERAVA in Mainland China
Everest and SPH Kyuan will work closely to promote import and channel distribution of XERAVA in China
Everest and SPH Kyuan will work closely to promote import and channel distribution of XERAVA in China
Study efficacy measures will include the expression of dystrophin protein and motor function.
Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare diseases.
Collaboration will enable rapid advancement of a joint preclinical proof of concept program for type 1 diabetes
The Award acknowledges Emcure's contribution in the field of HIV/AIDS to improve the quality of life of people living with HIV/AIDS.
The introduction of Octasa 1600 mg to the Canadian market is expected to increase the options for UC patients managed with mesalazine.
FDA’s NME approvals declined substantially in 2022, causing overall New Drug Application (NDA) approvals to drop
Venkat Nageswar Chalasani has been appointed as an Independent Director of Apitoria Pharma with effect from April 4, 2023
The summit encompasses multiple verticals, spanning from pharmaceuticals, biotech, life sciences, and the Healthcare sector to ensure an unbiased and comprehensive view on the future of the function.
Vikas Vij has been appointed as Chief Executive Officer (CEO) of the company
Subscribe To Our Newsletter & Stay Updated